Getein Biotech

Getein Biotech Operating Cash Flow

The Operating Cash Flow of Getein Biotech (603387.SS) as of Nov 8, 2026 is 392.59 M CNY. In the previous year, Operating Cash Flow was 423.00 M CNY — a change of -7.19% (lower).

Operating Cash Flow

392.59 MCNY

YoY

-7.19%

Last updated:

Operating Cash Flow of Getein Biotech is 2025 392.59 M CNY. Operating Cash Flow of Getein Biotech was 2024 423.00 M CNY. It decreases by -7.19% lower compared to the previous year.

The Getein Biotech Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
187.10 M CNY
Jan 1, 2019
225.73 M CNY
Jan 1, 2020
185.47 M CNY
Jan 1, 2021
432.36 M CNY
Jan 1, 2022
482.96 M CNY
Jan 1, 2023
333.22 M CNY
Jan 1, 2024
423.00 M CNY
Jan 1, 2025
392.59 M CNY
The Getein Biotech Operating Cash Flow history
YEAROperating Cash FlowYoY
392.59 MCNY-7.19%
423.00 MCNY+26.94%
333.22 MCNY-31.00%
482.96 MCNY+11.70%
432.36 MCNY+133.12%
185.47 MCNY-17.84%
225.73 MCNY+20.65%
187.10 MCNY-2.51%
191.91 MCNY+23.09%
155.91 MCNY+28.08%
121.73 MCNY+23.54%
98.53 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Operating Cash Flow of Getein Biotech is 392.59 M CNY in 2025.

Operating Cash Flow of Getein Biotech changed from 423.00 M CNY to 392.59 M CNY, representing a -7.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Getein Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Getein Biotech

All Key Metrics — Getein Biotech